These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10097243)

  • 1. Secondary prevention of myocardial infarction: role of beta-adrenergic blockers and angiotensin-converting enzyme inhibitors.
    Frishman WH; Cheng A
    Am Heart J; 1999 Apr; 137(4 Pt 2):S25-S34. PubMed ID: 10097243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACE inhibitors in heart failure: what more do we need to know?
    Demers C; Mody A; Teo KK; McKelvie RS
    Am J Cardiovasc Drugs; 2005; 5(6):351-9. PubMed ID: 16259523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of angiotensin converting-enzyme inhibitors and beta blockers on survival in elderly patients with reduced left ventricular function after myocardial infarction.
    Shlipak MG; Browner WS; Noguchi H; Massie B; Frances CD; McClellan M
    Am J Med; 2001 Apr; 110(6):425-33. PubMed ID: 11331052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
    Vantrimpont P; Rouleau JL; Wun CC; Ciampi A; Klein M; Sussex B; Arnold JM; Moyé L; Pfeffer M
    J Am Coll Cardiol; 1997 Feb; 29(2):229-36. PubMed ID: 9014971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.
    Shekelle PG; Rich MW; Morton SC; Atkinson CS; Tu W; Maglione M; Rhodes S; Barrett M; Fonarow GC; Greenberg B; Heidenreich PA; Knabel T; Konstam MA; Steimle A; Warner Stevenson L
    J Am Coll Cardiol; 2003 May; 41(9):1529-38. PubMed ID: 12742294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical algorithms for pharmacologic management of the post myocardial infarction patient.
    Reiffel JA; ;
    Clin Cardiol; 2005 Nov; 28(11 Suppl 1):I28-37. PubMed ID: 16450810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic therapies after myocardial infarction.
    Rapaport E; Gheorghiade M
    Am J Med; 1996 Oct; 101(4A):4A61S-69S; discussion 4A69S-70S. PubMed ID: 8900339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2.
    Barron HV; Michaels AD; Maynard C; Every NR
    J Am Coll Cardiol; 1998 Aug; 32(2):360-7. PubMed ID: 9708461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of angiotensin-converting enzyme inhibitors on ventricular remodeling and survival following myocardial infarction.
    Beckwith C; Munger MA
    Ann Pharmacother; 1993 Jun; 27(6):755-66. PubMed ID: 8329800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of digoxin, diuretics, beta blockers, angiotensin-converting enzyme inhibitors, and calcium channel blockers in older patients in an academic hospital-based geriatrics practice.
    Fishkind D; Paris BE; Aronow WS
    J Am Geriatr Soc; 1997 Jul; 45(7):809-12. PubMed ID: 9215330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of ischemic events with angiotensin-converting enzyme inhibitors: lessons and controversy emerging from recent clinical trials.
    Young JB
    Cardiovasc Drugs Ther; 1995 Feb; 9(1):89-102. PubMed ID: 7786840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Marked suppression of renin levels by beta-receptor blocker in patients treated with standard heart failure therapy: a potential mechanism of benefit from beta-blockade.
    Holmer SR; Hengstenberg C; Mayer B; Engel S; Löwel H; Riegger GA; Schunkert H
    J Intern Med; 2001 Feb; 249(2):167-72. PubMed ID: 11240846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
    Majumdar SR; McAlister FA; Cree M; Chang WC; Packer M; Armstrong PW;
    Clin Ther; 2004 May; 26(5):694-703. PubMed ID: 15220013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta-blocker in post-myocardial infarct survivors with preserved left ventricular systolic function.
    Siu CW; Pong V; Jim MH; Yue WS; Ho HH; Li SW; Lau CP; Tse HF
    Pacing Clin Electrophysiol; 2010 Jun; 33(6):675-80. PubMed ID: 20132502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients.
    Khalil ME; Basher AW; Brown EJ; Alhaddad IA
    J Am Coll Cardiol; 2001 Jun; 37(7):1757-64. PubMed ID: 11401108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE inhibitors in heart failure: an update.
    Smith WH; Ball SG
    Basic Res Cardiol; 2000; 95 Suppl 1():I8-14. PubMed ID: 11192359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta-blocker underuse in secondary prevention of myocardial infarction.
    Everly MJ; Heaton PC; Cluxton RJ
    Ann Pharmacother; 2004 Feb; 38(2):286-93. PubMed ID: 14742768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of combined beta-blocker and angiotensin-converting enzyme inhibitor treatment on 1-year survival after acute myocardial infarction: findings of the PRIAMHO-II registry].
    Arós F; Loma-Osorio A; Vila J; López-Bescós L; Cuñat J; Rodríguez E; San José JM; Heras M; Marrugat J;
    Rev Esp Cardiol; 2006 Apr; 59(4):313-20. PubMed ID: 16709383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.